News & Updates

Supplementation with resveratrol does not appear to provide much benefit in the management of cardiometabolic risk factors in patients with type 2 diabetes (T2D), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD), suggests a study.

Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.

Patients with type 2 diabetes (T2D) and arterial stiffness (AS) exhibit lower 25-hydroxyvitamin D (25[OH]D) and higher rate of vitamin D deficiency, a study has shown. In addition, a negative association exists between 25(OH)D and AS assessed by brachial-ankle pulse wave velocity (baPWV).

Selenium appears to reduce lipids and heighten the risk of type 2 diabetes (T2D), potentially via insulin resistance instead of pancreatic beta cell function, suggests a study.